Ourobionics entered into a non-exclusive agreement with Humabiologics, a US biotech company specializing in the development and commercialization of human biomaterials for regenerative medicine research applications. The partnership agreement allows Humabiologics to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European market. Under this agreement, European customers will have quick and convenient access to Humabiologics products through Ourobionics. By sharing the similar vision to empower research and making biofabrication processes more accessible, Ourobionics and Humabiologics will set a new standard to position themselves as industry leaders of advanced tissue engineering and regenerative therapies.
The use of animal products in research can lead to poor translation aspects, irrelevant outcomes, and regulatory hurdles that can slow the development of life science innovations. Humabiologics human-derived products are designed to address these challenges by offering high quality, supply-stable, and affordable native human-derived biomaterials for translational regenerative medicine therapies such as cell therapy, bioprinting, tissue & disease modeling, or drug screening. Humabiologics developed proprietary processes based on tissue industry quality system standards to manufacture its products and only partners with FDA-registered and accredited tissue banks around the US to utilize thoroughly screened donated human tissue that will not be used for transplant. Humabiologics product offerings are unique and include the most affordable native human skin collagen, first human bone gelatin, and native human extracellular matrix that can be used similarly to Matrigel, with more products being developed and will be launched soon based on market demand.
By developing and supplying up-to-date, cutting-edge technologies in biofabrication and tissue engineering, Ourobionics wants to offer complete, standardized processes to its customers and make the field of biofabrication more accessible to any professional with a vision and a purpose. Moreover, increasing the number of advanced technologies available for commercial use will set a new quality benchmark of biofabricated products (such as 3D cell cultures, organoids or ready-to-use tissue models) and unlock new, more complex applications. This shift is expected to help drive $40B global regenerative medicine market in the next 5 years.
Ourobionics and Humabiologics share the awareness of how precious the gift of life is and understand the value of extending the gift of donation. By joining forces, and offering unique and more clinically relevant products, both companies will actively pursue the mission to help as many people as possible.